Creative Medical Technology Holdings, Inc. (CELZ)
NASDAQ: CELZ · Real-Time Price · USD
2.550
+0.030 (1.19%)
Nov 20, 2024, 4:00 PM EST - Market closed
CELZ Employees
Creative Medical Technology Holdings had 4 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$2,750
Profits / Employee
-$1,329,495
Market Cap
4.46M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | 0 | - |
| Dec 31, 2021 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Biofrontera | 85 |
| Sunshine Biopharma | 44 |
| Aptevo Therapeutics | 40 |
| Predictive Oncology | 35 |
| Windtree Therapeutics | 20 |
| Galmed Pharmaceuticals | 8 |
| Pasithea Therapeutics | 8 |
| Portage Biotech | 7 |
CELZ News
- 8 days ago - Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment - GlobeNewsWire
- 4 months ago - Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program - GlobeNewsWire
- 4 months ago - Creative Medical Technology Holdings Provides Corporate Update - GlobeNewsWire
- 5 months ago - Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin - GlobeNewsWire
- 9 months ago - Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access - Business Wire
- 9 months ago - Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy - Business Wire
- 1 year ago - Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain - Accesswire
- 1 year ago - Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain - PRNewsWire